Ticker League

EBITDA for Biogen (BIIB)

Latest filings through · Reported

Metric

TTM

$2.70B

YoY change

+3.5%

5Y CAGR

-9.5%

Peak year (2019)

$7.74B

EBITDA history chart for Biogen (BIIB) from 1985 to 2025

Latest: $3.10B

EBITDA growth chart for Biogen (BIIB) from 1985 to 2025

Latest: +3.5%

EBITDA history table for Biogen (BIIB) from 1985 to 2025

  • 2025$3.10B+3.5%
  • 2024$3.00B+26.0%
  • 2023$2.38B-32.8%
  • 2022$3.54B-9.9%
  • 2021$3.92B-23.2%
  • 2020$5.11B-34.0%
  • 2019$7.74B+10.3%
  • 2018$7.01B+6.2%
  • 2017$6.61B+4.1%
  • 2016$6.35B+13.0%
  • 2015$5.62B+21.9%
  • 2014$4.60B+52.4%
  • 2013$3.02B+37.1%
  • 2012$2.20B+4.8%
  • 2011$2.10B+29.7%
  • 2010$1.62B-9.7%
  • 2009$1.80B+7.6%
  • 2008$1.67B+25.4%
  • 2007$1.33B+53.2%
  • 2006$868.93M+30.1%
  • 2005$668.05M+27.9%
  • 2004$522.43M-165.0%
  • 2003−$804.13M-412.0%
  • 2002$257.75M-40.1%
  • 2001$430.47M-18.8%
  • 2000$530.45M+52.7%
  • 1999$347.35M+61.4%
  • 1998$215.23M+27.9%
  • 1997$168.26M+200.0%
  • 1996$56.09M+205.5%
  • 1995$18.36M+198.6%
  • 1994$6.15M-78.3%
  • 1993$28.40M-20.4%
  • 1992$35.70M+839.5%
  • 1991$3.80M-17.4%
  • 1990$4.60M-180.7%
  • 1989−$5.70M-35.2%
  • 1988−$8.80M-56.9%
  • 1987−$20.40M-18.4%
  • 1986−$25.00M-12.0%
  • 1985−$28.40M—

EBITDA values are taken from Biogen's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.

About EBITDA at Biogen (BIIB)

According to Biogen's latest reported financial statements, the company's current EBITDA (TTM) is $2.70B. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.

Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .

2025's annual EBITDA for Biogen (BIIB) came in at $3.10B – edged up 3.5% year-over-year.

Across 2020–2025 (5 years), Biogen EBITDA produced a CAGR of -9.5% – sustaining 2 straight years of year-over-year growth.

Biogen EBITDA plunged from $7.74B in 2019 to $3.10B in 2025, a 59.9% drawdown.

The highest annual EBITDA of $7.74B was reported in 2019. The lowest in the available history was −$804.13M in 2003.

Biogen EBITDA by Year

Biogen EBITDA 2025: $3.10B

Biogen posted EBITDA of $3.10B in 2025, edged up 3.5% from 2024.

Biogen EBITDA 2024: $3.00B

In 2024, Biogen reported EBITDA of $3.00B, grew 26.0% from 2023.

Biogen EBITDA 2023: $2.38B

Biogen EBITDA in 2023 was $2.38B, plunged 32.8% below 2022.

Biogen EBITDA 2022: $3.54B

2022's EBITDA for Biogen came in at $3.54B, declined 9.9% below 2021.

Biogen EBITDA 2021: $3.92B

Biogen EBITDA in 2021 was $3.92B.

See more financial history for Biogen (BIIB).

Sector peers by EBITDA

Healthcare peers of Biogen (BIIB), ranked by their latest EBITDA

Frequently asked questions

Biogen (BIIB) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation